Clinical Trials
31 trialsNCT07174336 2026-06-04
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT05827081 2026-06-03
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT05952557 2026-05-28
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT07062965 2026-05-06
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT05306340 2026-04-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT05514054 2026-04-02
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07024173 2026-01-26
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT04906395 2026-01-13
OVELIA
Tolmar Inc.
Phase 3 Active not recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT04869943 2024-01-26
ARTEST
Veru Inc.
Phase 3 Terminated
NCT02482753 2022-01-12
Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT03538171 2021-07-09
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 3 Unknown
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT01626222 2017-02-23
MACS2096
Novartis
Phase 3 Completed
NCT00036270 2015-10-28
TEAM
Pfizer
Phase 3 Completed
NCT00065325 2015-02-24
EFECT
AstraZeneca
Phase 3 Completed
NCT00038467 2014-05-07
IES
Pfizer
Phase 3 Completed
NCT00143390 2012-01-25
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Pfizer
Phase 3 Completed
NCT00279448 2011-12-23
TEAM
Pfizer
Phase 3 Completed
NCT00944918 2011-08-29
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
AstraZeneca
Phase 3 Completed
NCT01237327 2011-05-06
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Pfizer
Phase 3 Completed